• Corbus Pharmaceuticals appointed Leonardo Viana Nicacio as chief medical officer as it prepares to start the TEMPO-1 registrational study of CRB-701 this summer.
• Nicacio previously served as chief medical officer at Protara Therapeutics.
• He also held senior clinical development roles at Stemline Therapeutics, Seagen, AstraZeneca, Flatiron Health, Sanofi, and YM Biosciences.
• Corbus is targeting a late-summer topline readout from the CANYON-1 Phase 1b obesity study of CRB-913.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060800PRIMZONEFULLFEED9757098) on July 06, 2026, and is solely responsible for the information contained therein.